Target
respiratory syncytial virus
Description
Anti-respiratory syncytial virus Antibody, Highly Galactosylated (BioBet-GA-427ZP) is a humanized IgG1, κ antibody against respiratory syncytial virus which contains with a high level of galactosylation.
Antibody Indication
Respiratory Syncytial Virus (RSV) disease
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced respiratory syncytial virus antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Clone
BioBet-GA-427ZP
Description
The Highly Galactosylated Anti-respiratory syncytial virus (Felvizumab), a biobetter antibody contains with a high level of galactosylation.
Antibody Indication
Respiratory Syncytial Virus (RSV) disease
